<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08-PONE-RA-06170R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0004719</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Genetics and Genomics/Disease Models</subject><subject>Genetics and Genomics/Genetics of Disease</subject><subject>Immunology/Genetics of the Immune System</subject><subject>Immunology/Immune Response</subject><subject>Immunology/Innate Immunity</subject><subject>Gastroenterology and Hepatology/Inflammatory Bowel Disease</subject></subj-group></article-categories><title-group><article-title>IBD-Associated <italic>TL1A</italic> Gene (<italic>TNFSF15</italic>) Haplotypes Determine Increased Expression of TL1A Protein</article-title><alt-title alt-title-type="running-head"><italic>TL1A</italic> Haplotypes and Expression</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Michelsen</surname><given-names>Kathrin S.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>Lisa S.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>Kent D.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Qi T.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mei</surname><given-names>Ling</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Landers</surname><given-names>Carol J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Derkowski</surname><given-names>Carrie</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>McGovern</surname><given-names>Dermot P. B.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rotter</surname><given-names>Jerome I.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Targan</surname><given-names>Stephan R.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Inflammatory Bowel Disease Center &#x00026; Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Timmer</surname><given-names>Antje</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">HelmholtzZentrum M&#x000fc;nchen, Germany</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>targans@cshs.org</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: KSM LST DM JIR SRT. Performed the experiments: KSM LST KDT QTY LM CL. Analyzed the data: KSM LST KDT QTY LM CL CD. Contributed reagents/materials/analysis tools: CL. Wrote the paper: KSM KDT DM JIR SRT. Coordinated the research study and recruited patients: CD.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>5</day><month>3</month><year>2009</year></pub-date><volume>4</volume><issue>3</issue><elocation-id>e4719</elocation-id><history><date date-type="received"><day>24</day><month>7</month><year>2008</year></date><date date-type="accepted"><day>12</day><month>1</month><year>2009</year></date></history><copyright-statement>Michelsen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><sec><title>Background</title><p>The recently identified member of the TNF superfamily TL1A (<italic>TNFSF15</italic>) increases IFN-&#x003b3; production by T cells in peripheral and mucosal CCR9&#x0002b; T cells. TL1A and its receptor DR3 are up-regulated during chronic intestinal inflammation in ulcerative colitis and Crohn's disease (CD). <italic>TL1A</italic> gene haplotypes increase CD susceptibility in Japanese, European, and US cohorts.</p></sec><sec><title>Methodology and Principal Findings</title><p>Here we report that the presence of <italic>TL1A</italic> gene haplotype B increases risk in Jewish CD patients with antibody titers for the E. coli outer membrane porin C (OmpC&#x0002b;) (Haplotype B frequency in Jewish CD patients: 24.9&#x00025; for OmpC negative and 41.9&#x00025; for OmpC positive patients, respectively, P&#x02264;0.001). CD14&#x0002b; monocytes isolated from Jewish OmpC&#x0002b; patients homozygous for <italic>TL1A</italic> gene haplotype B express higher levels of TL1A in response to Fc&#x003b3;R stimulation, a known inducing pathway of TL1A, as measured by ELISA. Furthermore, the membrane expression of TL1A is increased on peripheral monocytes from Jewish but not non-Jewish CD patients with the risk haplotype.</p></sec><sec><title>Conclusions and Significance</title><p>These findings suggest that <italic>TL1A</italic> gene variation exacerbates induction of TL1A in response to Fc&#x003b3;R stimulation in Jewish CD patients and this may lead to chronic intestinal inflammation via overwhelming T cell responses. Thus, TL1A may provide an important target for therapeutic intervention in this subgroup of IBD patients.</p></sec></abstract><counts><page-count count="11"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>TL1A, a recently identified member of the TNF superfamily, increases IL-2 response by anti-CD3/CD28-stimulated T cells <xref ref-type="bibr" rid="pone.0004719-Migone1">&#x0005b;1&#x0005d;</xref>. Furthermore, we and others have shown that TL1A synergizes with IL-12 and IL-18 to augment IFN-&#x003b3; release in human T and NK cells and biases T cell differentiation towards a T<sub>H</sub>1 phenotype <xref ref-type="bibr" rid="pone.0004719-Bamias1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Papadakis1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Papadakis2">&#x0005b;4&#x0005d;</xref>. TL1A expression is increased in inflamed tissue of colon and small bowel of CD patients and colocalizes to macrophages and T cells <xref ref-type="bibr" rid="pone.0004719-Bamias1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Prehn1">&#x0005b;5&#x0005d;</xref>. In particular, lamina propria, but also peripheral CD4&#x0002b;CCR9&#x0002b; T cells, constitutively express membrane TL1A and are especially sensitive to TL1A stimulation <xref ref-type="bibr" rid="pone.0004719-Papadakis1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Papadakis2">&#x0005b;4&#x0005d;</xref>. In murine models of ileitis, TL1A is mainly expressed on lamina propria dendritic cells <xref ref-type="bibr" rid="pone.0004719-Bamias2">&#x0005b;6&#x0005d;</xref>.</p><p>We have recently demonstrated that TL1A is produced by antigen-presenting cells, e.g. monocytes and dendritic cells, in response to Fc&#x003b3;R signaling but not in response to Toll-like receptor agonists or pro-inflammatory cytokines <xref ref-type="bibr" rid="pone.0004719-Prehn2">&#x0005b;7&#x0005d;</xref>. Stimulation with Immune Complexes (IC) leads to the expression of both membrane and secreted TL1A <xref ref-type="bibr" rid="pone.0004719-Migone1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Prehn2">&#x0005b;7&#x0005d;</xref>. Neutralizing TL1A antibodies prevent and treat colitis in a murine model of chronic colitis by affecting both T<sub>H</sub>1 and T<sub>H</sub>17 responses, suggesting that TL1A is a central regulator of intestinal inflammation during colitis <xref ref-type="bibr" rid="pone.0004719-Takedatsu1">&#x0005b;8&#x0005d;</xref>. In addition, it has been demonstrated recently that TL1A also plays an important role in the pathogenesis of other inflammatory diseases, such as Experimental Autoimmune Encephalomyelitis (EAE) and allergic lung inflammation <xref ref-type="bibr" rid="pone.0004719-Fang1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Meylan1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Pappu1">&#x0005b;11&#x0005d;</xref>.</p><p>The first genome-wide association study of CD provided evidence that variation in <italic>TNFSF15</italic>, the <italic>TL1A</italic> gene, contribute to CD in Japanese and both CD and ulcerative colitis in the British population <xref ref-type="bibr" rid="pone.0004719-Yamazaki1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Kakuta1">&#x0005b;13&#x0005d;</xref>. Haplotypes composed of 5 <italic>TNFSF15</italic> SNPs were observed to confer significant CD risk (<italic>haplotype A</italic>) and protection (<italic>haplotype B</italic>), using both case/control and family-based study designs <xref ref-type="bibr" rid="pone.0004719-Yamazaki1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Kakuta1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Barrett1">&#x0005b;14&#x0005d;</xref>. We have also observed a protective association between CD and the same <italic>haplotype B</italic> in a Los Angeles based cohort <xref ref-type="bibr" rid="pone.0004719-Picornell1">&#x0005b;15&#x0005d;</xref>. Stratification on Ashkenazi Jewish ethnicity suggested that <italic>haplotype B</italic> may have a different effect on CD susceptibility in the Jewish and non-Jewish populations. In contrast to the protective association seen in non-Jews, the opposite trend towards a risk association with <italic>haplotype B</italic> was observed in Ashkenazi Jews <xref ref-type="bibr" rid="pone.0004719-Picornell1">&#x0005b;15&#x0005d;</xref>. Similar observation of differential genetic risk association in diverse ethnic groups have been made in CD, in ulcerative colitis and other gentically complex diseases including schizophrenia and asthma <xref ref-type="bibr" rid="pone.0004719-Funke1">&#x0005b;16&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Li1">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Ober1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Silverberg1">&#x0005b;19&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Sugimura1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Tountas1">&#x0005b;21&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-VanDenBogaert1">&#x0005b;22&#x0005d;</xref>. Jewish CD patients carrying the <italic>TNFSF15 haplotype B</italic> were more likely to have more severe CD, as evidenced by a higher rate of surgery <xref ref-type="bibr" rid="pone.0004719-Picornell1">&#x0005b;15&#x0005d;</xref> and by the expression of antibody responses to microbial antigens, including the <italic>E. coli</italic> outer membrane porin C (OmpC&#x0002b;) <xref ref-type="bibr" rid="pone.0004719-Mow1">&#x0005b;23&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Arnott1">&#x0005b;24&#x0005d;</xref>. To date, no functional basis for the relationship between <italic>TNFSF15</italic> variation and disease severity in CD patients has been shown.</p><p>In order to determine the functional consequences of <italic>TNFSF15</italic> genetic variation, we have identified subjects for immunological studies based on <italic>TNFSF15 haplotypes</italic>. Here we show that, in Jewish CD patients with seropositivity for OmpC, the TL1A risk haplotype <italic>TNFSF15 haplotype B</italic> is associated with higher TL1A expression upon stimulation of Fc&#x003b3;R. Furthermore, Jewish but not non-Jewish CD patients with the <italic>TNFSF15</italic> risk <italic>haplotype B</italic> have a higher baseline expression of TL1A on peripheral monocytes, suggesting a higher baseline capacity for T cell stimulation. Collectively, our data define a role for <italic>TNFSF15</italic> genetic variation in determining disease severity in Jewish CD patients, and support the concept that TL1A is a novel interventional target, at least for the subgroup of Jewish, OmpC&#x0002b;, CD patients.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Human subjects</title><p>We collected peripheral blood from randomly selected patients attending the IBD center at Cedars-Sinai Medical Center who had previously been diagnosed with CD according to standard clinical, endoscopic, radiological, and histological findings. Written informed consent was obtained from all patients. Procedures were approved by the Institutional Review Board of Cedars-Sinai Medical Center (IRB number 3358 and 2673). The patient's demographics, diagnoses and medications at time of sample collection are provided in <xref ref-type="table" rid="pone-0004719-t001">Table 1</xref>. The medications were equivalent in the different groups. Jewish ethnicity was defined as previously described by one or more grandparents of Ashkenazi Jewish descent <xref ref-type="bibr" rid="pone.0004719-Roth1">&#x0005b;25&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Yang1">&#x0005b;26&#x0005d;</xref>. Controls were matched for ethnicity and were usually spouses of CD patients.</p><table-wrap id="pone-0004719-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004719.t001</object-id><label>Table 1</label><caption><title>Patient's demographic, diagnoses, medications.</title></caption><graphic id="pone-0004719-t001-1" xlink:href="pone.0004719.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004719-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Ethnicity</td><td align="left" rowspan="1" colspan="1">tnfsf15 haplotype_a</td><td align="left" rowspan="1" colspan="1">tnfsf15 haplotype_b</td><td align="left" rowspan="1" colspan="1">OMPC status</td><td align="left" rowspan="1" colspan="1">Disease Activity</td><td align="left" rowspan="1" colspan="1">Current IBD Medications</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Inactive</td><td align="left" rowspan="1" colspan="1">Asacol</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Inactive</td><td align="left" rowspan="1" colspan="1">Asacol, Purinethol</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Inactive</td><td align="left" rowspan="1" colspan="1">Asacol, 6-MP</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Inactive</td><td align="left" rowspan="1" colspan="1">Asacol, Remicade every 10 wks</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">not B</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Remicade</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Active</td><td align="left" rowspan="1" colspan="1">Remicade</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Inactive</td><td align="left" rowspan="1" colspan="1">Pentasa, 6-MP</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">not A</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Inactive</td><td align="left" rowspan="1" colspan="1">Asacol. 6-MP</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">not A</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Inactive</td><td align="left" rowspan="1" colspan="1">Budesonide</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">not A</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Active</td><td align="left" rowspan="1" colspan="1">Remicade monthly</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Active</td><td align="left" rowspan="1" colspan="1">Entocort</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Inactive</td><td align="left" rowspan="1" colspan="1">6-MP, Remicade every 3 months</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Prednisone, Pentasa</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">not A</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Active Mild-Moderate</td><td align="left" rowspan="1" colspan="1">Asacol, 6-MP</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Inactive</td><td align="left" rowspan="1" colspan="1">6-MP, Asacol, Remicade every 8 wks</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Sulfasalazine</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Pentasa</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Active</td><td align="left" rowspan="1" colspan="1">AZA</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Active Mildly</td><td align="left" rowspan="1" colspan="1">6-MP, Asacol</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Pentasa</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Prednisone</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6-MP</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Imuran, asulfidine</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Asacol</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Active</td><td align="left" rowspan="1" colspan="1">Entocort, Colazal, Canasa supp.</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Asathioprine</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">not A</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Active Mildly</td><td align="left" rowspan="1" colspan="1">Prednisone, 6-MP</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">not A</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Pentasa</td></tr><tr><td align="left" rowspan="1" colspan="1">Jewish</td><td align="left" rowspan="1" colspan="1">not A</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Purinethol</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Active</td><td align="left" rowspan="1" colspan="1">None (Digest-tinol, aloe-based)</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Active Mildly</td><td align="left" rowspan="1" colspan="1">Imuran, Pentasa</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Prednisone, Cipro, Xifaxin</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Inactive</td><td align="left" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Inactive</td><td align="left" rowspan="1" colspan="1">Prednisone, Pentasa, Xifaxan</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Inactive bordering active</td><td align="left" rowspan="1" colspan="1">6-MP, Pentasa, Remicade</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Colazal</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Active</td><td align="left" rowspan="1" colspan="1">6-MP, Pentasa, Thalidomide</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">not A</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Entocort, 6-MP</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">not A</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Remicade</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Inactive</td><td align="left" rowspan="1" colspan="1">6-MP</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Active Mildly</td><td align="left" rowspan="1" colspan="1">Asacol, Remicade</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Active</td><td align="left" rowspan="1" colspan="1">Humira</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Active</td><td align="left" rowspan="1" colspan="1">Cansa supp.</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Active</td><td align="left" rowspan="1" colspan="1">Asacol, 6-MP, Remicade</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Inactive</td><td align="left" rowspan="1" colspan="1">AZA</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Inactive</td><td align="left" rowspan="1" colspan="1">Asacol</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Inactive</td><td align="left" rowspan="1" colspan="1">Prednisone</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Inactive</td><td align="left" rowspan="1" colspan="1">Humira; Cipro, Flagyl</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Active Mildly</td><td align="left" rowspan="1" colspan="1">None (other than curcumin, vitamins)</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Active</td><td align="left" rowspan="1" colspan="1">Prednisone, Humira</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">not A</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Active</td><td align="left" rowspan="1" colspan="1">Remicade</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Active Mildly</td><td align="left" rowspan="1" colspan="1">Pentasa, Remicade</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Active</td><td align="left" rowspan="1" colspan="1">6-MP, Pentasa, Entocort</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">not A</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Inactive</td><td align="left" rowspan="1" colspan="1">6-MP</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">not A</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Active</td><td align="left" rowspan="1" colspan="1">Pentasa, Curcumin, Probiotics</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">not A</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Active</td><td align="left" rowspan="1" colspan="1">Humira</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">not A</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Active Mildly</td><td align="left" rowspan="1" colspan="1">Humira</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Inactive</td><td align="left" rowspan="1" colspan="1">Remicade; prednisone</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Active Mildly</td><td align="left" rowspan="1" colspan="1">Asacol, Prednisone</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">not A</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Active Mildly</td><td align="left" rowspan="1" colspan="1">6-MP, Asacol</td></tr><tr><td align="left" rowspan="1" colspan="1">non Jewish</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">negative</td><td align="left" rowspan="1" colspan="1">Active Mildly</td><td align="left" rowspan="1" colspan="1">Remicade</td></tr></tbody></table></table-wrap></sec><sec id="s2b"><title>TNFSF15 genotyping and haplotype assignment</title><p>Single nucleotide polymorphisms (SNPs) <italic>rs3810936, rs6478108, rs6478109, rs7848647</italic>, and <italic>rs7869487</italic> were genotyped using either Illumina Golden Gate technology <xref ref-type="bibr" rid="pone.0004719-Fan1">&#x0005b;27&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Shen1">&#x0005b;28&#x0005d;</xref> or ABI TaqMan MGB technology <xref ref-type="bibr" rid="pone.0004719-Kutyavin1">&#x0005b;29&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Livak1">&#x0005b;30&#x0005d;</xref> following the manufacturer's protocols (Illumina, San Diego, CA; ABI, Foster City, CA). Assays for these SNPs are available to other researchers through ABI as follows: <italic>rs3810936, hCV363308; rs6478108, hCV170492; rs6478109, hCV1305297; rs7848647, hCV11277159;</italic> and <italic>rs7869487, hCV11277149</italic>. Consistency between the two methods has been confirmed in our laboratory by genotyping over 200 samples with both methods. Details of the positions of these SNPs with respect to the <italic>TNFSF15</italic> gene and the haplotypes from the individual SNPs are shown in <xref ref-type="fig" rid="pone-0004719-g001">Figure 1</xref>. While redundancy in the 5 SNPs may be apparent from <xref ref-type="fig" rid="pone-0004719-g001">Figure 1</xref>, all 5 SNPs are retained in this study in order to (1) distinguish the major haplotypes from minor haplotypes with low frequencies (data not shown) and (2) retain the haplotype terminology of the previous reports <xref ref-type="bibr" rid="pone.0004719-Yamazaki1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Kakuta1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Picornell1">&#x0005b;15&#x0005d;</xref>. Haplotypes were assigned from the individual SNP data using Phase v2 and the probability of assignment was greater than 95&#x00025;. Association of haplotypes with the presence of antibody per subject was tested by chi-square and the significance was estimated by permutation (Jewish OmpC&#x02212;: N&#x0200a;&#x0003d;&#x0200a;304, Jewish OmpC&#x0002b;: N&#x0200a;&#x0003d;&#x0200a;196, non-Jewish OmpC&#x02212;: N&#x0200a;&#x0003d;&#x0200a;434, non-Jewish OmpC&#x0002b;: N&#x0200a;&#x0003d;&#x0200a;234).</p><fig id="pone-0004719-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004719.g001</object-id><label>Figure 1</label><caption><title><italic>TL1A (TNFSF15)</italic> gene and haplotype structure and association with Crohn's Disease.</title><p>(A) The <italic>TNFSF15</italic> gene is on the reverse strand of NCBI human genome build 36 at the position shown on <italic>chromosome 9</italic> but is shown 5&#x02032; to 3&#x02032; in keeping with the previous reports. The dotted line represents genomic sequence, solid line the gene sequence, thin bars untranslated regions, and thick bars the exons. (B) Single nucleotide polymorphisms (SNPs) genotyped for this study are listed with their relative positions along the gene. (C) Definition of haplotypes assigned in this study. The nucleotide assignments follow the previous report and correspond to the sense strand of the gene. The numbers 26, 31, 35, 36, and 41 refer to previous reports <xref ref-type="bibr" rid="pone.0004719-Yamazaki1">&#x0005b;12&#x0005d;</xref>. (D) Frequency of CD patients as a function of OmpC status for TL1A haplotype B for Jewish and non-Jewish CD patients, respectively (P&#x02264;0.001).</p></caption><graphic xlink:href="pone.0004719.g001"/></fig></sec><sec id="s2c"><title>Serological Analysis</title><p>Sera were analyzed for expression of anti-OmpC antibodies by ELISA as previously described <xref ref-type="bibr" rid="pone.0004719-Landers1">&#x0005b;31&#x0005d;</xref>.</p></sec><sec id="s2d"><title>Isolation of CD14<sup>&#x0002b;</sup> monocytes from patient's blood</title><p>Blood was obtained from patients after informed consent in accordance with procedures established by the Cedars-Sinai Institutional Review Board. Monocytes were isolated from PBMC as described previously <xref ref-type="bibr" rid="pone.0004719-Prehn2">&#x0005b;7&#x0005d;</xref>.</p></sec><sec id="s2e"><title>Cell culture and stimulation</title><p>Plate-bound, cross-linked human IgG (IC) was prepared as described previously <xref ref-type="bibr" rid="pone.0004719-Prehn2">&#x0005b;7&#x0005d;</xref>. Monocytes were incubated with IC for the indicated time-points.</p></sec><sec id="s2f"><title>ELISA</title><p>TL1A was quantified in undiluted supernatants from stimulated cells using an ELISA and Ab developed at Teva Pharmaceutical USA as described elsewhere <xref ref-type="bibr" rid="pone.0004719-Prehn2">&#x0005b;7&#x0005d;</xref>.</p></sec><sec id="s2g"><title>Flow cytometry</title><p>Monocytes stimulated with IC or bacteria for 16 h were stained with the TL1A Ab as described previously <xref ref-type="bibr" rid="pone.0004719-Prehn2">&#x0005b;7&#x0005d;</xref>. Cells were analyzed on a CyAn&#x02122; ADP flow cytometer (Dako Cytomation, Carpinteria, CA) and analyzed with the Summit 4.1 software package (Dako).</p></sec><sec id="s2h"><title>Statistics</title><p>Statistical significance between groups was determined by Student's <italic>t</italic> test. A value of <italic>p</italic>&#x02264;0.05 was considered to be statistically significant.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Association of <italic>TNFSF15 (TL1A) haplotype B</italic> and the serum expression of anti-OmpC in Jewish Crohn's disease patients</title><p>Since the expression of anti-OmpC in CD patients is a familial trait and has been associated with severe CD <xref ref-type="bibr" rid="pone.0004719-Mow1">&#x0005b;23&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Arnott1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Mei1">&#x0005b;32&#x0005d;</xref>, we tested the association between <italic>TNFSF15 haplotype B</italic> and the serum expression of anti-OmpC in Ashkenazi Jewish and non-Jewish CD patients (<xref ref-type="fig" rid="pone-0004719-g001">Figure 1A&#x02013;D</xref>). <italic>TNFSF15 haplotypes</italic> were assigned from individual SNP data using PHASE v2 with a probability greater than 95&#x00025; (see <xref ref-type="fig" rid="pone-0004719-g001">Figure 1A&#x02013;C</xref> for details of SNPs and haplotypes). In non-Jewish CD subjects, there was no difference in the frequency of <italic>haplotype B</italic> between OmpC positive and OmpC negative subjects (OmpC negative 38.6&#x00025;, OmpC positive 38.3&#x00025;; <xref ref-type="fig" rid="pone-0004719-g001">Figure 1D</xref>). The frequency of haplotype B in either group was similar to that previously observed for all CD in non-Jewish subjects <xref ref-type="bibr" rid="pone.0004719-Picornell1">&#x0005b;15&#x0005d;</xref>. In contrast, for Jewish CD subjects the frequency of <italic>haplotype B</italic> was significantly higher in OmpC positive subjects compared with OmpC negative subjects (<xref ref-type="fig" rid="pone-0004719-g001">Figure 1 D</xref>) (24.9&#x00025; OmpC negative, 41.9&#x00025; OmpC positive, P&#x02264;0.001). The frequency of <italic>haplotype B</italic> in OmpC negative subjects was lower and in OmpC positive subjects was higher than that previously observed for all CD in Jewish subjects (32&#x00025;) <xref ref-type="bibr" rid="pone.0004719-Picornell1">&#x0005b;15&#x0005d;</xref> (<xref ref-type="fig" rid="pone-0004719-g001">Figure 1D</xref>). In addition, the level of anti-OmpC expression was higher in <italic>TNFSF15 (TL1A) haplotype B</italic> Jewish subjects (the median level of anti-OmpC was 23.9 ELISA units in Jewish CD patients with haplotype B compared with 14.9 in Jewish CD patients without <italic>haplotype B</italic>, P wilcoxon test &#x02264;0.001). The frequency of OmpC seropositivity in Jewish CD patients with <italic>haplotype B</italic> is 52&#x00025;, and 36&#x00025; in non-Jewish CD patients with <italic>haplotype B</italic>. We did not observe an association between other CD-associated antibodies to microbial antigens (e.g. anti-Cbir1 antibodies, anti-I2 antibodies, anti-ASCA antibodies) and differences in <italic>haplotype B</italic> frequency in Jewish or non-Jewish CD patients (data not shown).</p></sec><sec id="s3b"><title><italic>TNFSF15 (TL1A) haplotypes</italic> in Jewish IBD patients results in differential TL1A expression in monocytes stimulated with IC</title><p>To determine if the different <italic>TNFSF15 (TL1A) haplotypes</italic> associated with CD in Jewish patients correlate with functional consequences in TL1A expression, we isolated CD14&#x0002b; monocytes from Jewish and non-Jewish CD patients with <italic>haplotypes A</italic> or <italic>B</italic>, and stimulated them with immune complexes (IC), a known inducer of TL1A gene expression <xref ref-type="bibr" rid="pone.0004719-Prehn2">&#x0005b;7&#x0005d;</xref>. We observed strong induction of TL1A secretion in response to IC in Jewish <italic>haplotype B</italic> carriers at 6 h of stimulation. Compared to Jewish <italic>haplotype A</italic> carriers, the secretion was significantly increased at 6 h in <italic>haplotype B</italic> carriers (<xref ref-type="fig" rid="pone-0004719-g002">Figure 2A</xref>). At 16 h we also observed an increase, although not significant (p&#x0200a;&#x0003d;&#x0200a;0.22), in secretion of TL1A in <italic>haplotype B</italic> compared to <italic>haplotype A</italic> Jewish patients (<xref ref-type="fig" rid="pone-0004719-g002">Figure 2A</xref>). In non-Jewish CD patients we also observed a significant difference between TL1A secretion in <italic>haplotypes A</italic> and <italic>B</italic> at 6 h of IC stimulation (<xref ref-type="fig" rid="pone-0004719-g002">Figure 2B</xref>). <italic>Haplotype B</italic> carriers secreted significantly more TL1A at 6 h compared to <italic>haplotype A</italic> carriers. At 16 h the difference in TL1A secretion between the haplotypes were not significant (p&#x0200a;&#x0003d;&#x0200a;0.29), although we observed a higher secretion in <italic>haplotype B</italic> non-Jewish patients. To determine if there are ethnic differences in expression of TL1A we compared Jewish and non-Jewish <italic>haplotype B</italic> carriers. Jewish <italic>haplotype B</italic> carriers secreted significant more TL1A at 6 h compared to non-Jewish <italic>haplotype B</italic> (p&#x0200a;&#x0003d;&#x0200a;0.002). At 16 h we did not observe any differences in the IC-induced secretion of TL1A (p&#x0200a;&#x0003d;&#x0200a;0.49). Next, we compared the TL1A secretion in Jewish and non-Jewish <italic>haplotype A</italic> carriers. There were no differences in the IC-induced secretion of TL1A in Jewish or non-Jewish CD <italic>haplotype A</italic> patients at 6 or 16 h (p&#x0200a;&#x0003d;&#x0200a;0.07 and 0.09, respectively).</p><fig id="pone-0004719-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004719.g002</object-id><label>Figure 2</label><caption><title>The <italic>B</italic> risk haplotype is associated with increased TL1A secretion in CD patients.</title><p>Monocytes from Jewish and non-Jewish patients with A, or B haplotypes were stimulated with IC for 6 or 16 h. Cell culture supernatants were analyzed for TL1A secretion by ELISA. (A) Monocytes from Jewish patients with A or B haplotypes were stimulated with IC for 6 or 16 h (n&#x0200a;&#x0003d;&#x0200a;15 and 12 for <italic>haplotype A</italic> and <italic>haplotype B</italic>, respectively, &#x0002a;, P&#x02264;0.002). All data represent the mean&#x000b1;SD. (B) Monocytes from non-Jewish patients with <italic>A</italic> or <italic>B haplotypes</italic> were stimulated with IC for 6 or 16 h (n&#x0200a;&#x0003d;&#x0200a;13 and 15 for <italic>haplotype A</italic> and <italic>haplotype B</italic>, respectively, &#x0002a;, P&#x02264;0.05).</p></caption><graphic xlink:href="pone.0004719.g002"/></fig><p>To determine if the observed differences in TL1A secretion also relate to differences in surface TL1A expression, we determined the expression of membrane TL1A as measured by the percentage of TL1A<sup>&#x0002b;</sup> monocytes and mean fluorescence intensity (MFI) after IC stimulation (<xref ref-type="fig" rid="pone-0004719-g003">Figure 3</xref>). We did not observe any significant differences in the percentage of control or IC-stimulated TL1A<sup>&#x0002b;</sup> monocytes in Jewish <italic>haplotype B</italic> carriers compared to <italic>haplotype A</italic> carriers (<xref ref-type="fig" rid="pone-0004719-g003">Figure 3A</xref>, p&#x0200a;&#x0003d;&#x0200a;0.19 and p&#x0200a;&#x0003d;&#x0200a;0.49 for control and IC stimulation, respectively). Furthermore, we also did not observe any significant differences in the percentage of control or IC-stimulated TL1A<sup>&#x0002b;</sup> monocytes in non- Jewish <italic>haplotype B</italic> carriers compared to <italic>haplotype A</italic> carriers (<xref ref-type="fig" rid="pone-0004719-g003">Figure 3B</xref>, p&#x0200a;&#x0003d;&#x0200a;0.83 and p&#x0200a;&#x0003d;&#x0200a;0.72 for control and IC stimulation, respectively). When we analyzed MFI of TL1A staining we observed an increase in MFI in Jewish <italic>haplotype B</italic> compared to <italic>haplotype A</italic> carriers, although this increase did not reach significance (<xref ref-type="fig" rid="pone-0004719-g003">Figure 3C</xref>, p&#x0200a;&#x0003d;&#x0200a;0.66 and p&#x0200a;&#x0003d;&#x0200a;0.52 for control and IC stimulation, respectively). We did not observe any differences in MFI in non-Jewish <italic>haplotype B</italic> compared to <italic>haplotype A</italic> carriers (<xref ref-type="fig" rid="pone-0004719-g003">Figure 3D</xref>, p&#x0200a;&#x0003d;&#x0200a;0.56 and p&#x0200a;&#x0003d;&#x0200a;0.91 for control and IC stimulation, respectively). In summary, Jewish and non-Jewish <italic>haplotype B</italic> carriers secrete significantly more TL1A in response to IC compared to <italic>haplotype A</italic> carriers at 6 h (<xref ref-type="table" rid="pone-0004719-t002">Table 2</xref>). Furthermore, Jewish <italic>haplotype B</italic> carriers secrete significantly more TL1A compared to non-Jewish <italic>haplotype B</italic> carriers (<xref ref-type="fig" rid="pone-0004719-g002">Figure 2C</xref>). In contrast, we did not observe any significant differences in TL1A surface expression in patients with different haplotypes in either Jewish or non-Jewish CD patients (<xref ref-type="table" rid="pone-0004719-t002">Table 2</xref>).</p><fig id="pone-0004719-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004719.g003</object-id><label>Figure 3</label><caption><title><italic>Haplotype A</italic> and <italic>B</italic> have similar TL1A surface expressions in Jewish and non-Jewish CD patients.</title><p>(A) Monocytes from Jewish patients with <italic>A</italic> or <italic>B haplotypes</italic> were stimulated with IC for 16 h. Monocytes were stained with an anti-TL1A antibody and analyzed by flow cytometry. Data are presented as &#x00025; of TL1A<sup>&#x0002b;</sup> monocytes (n&#x0200a;&#x0003d;&#x0200a;11 and 9 for <italic>haplotype A</italic> and <italic>haplotype B</italic>, respectively, P&#x0200a;&#x0003d;&#x0200a;0.19 and P&#x0200a;&#x0003d;&#x0200a;0.49 for control and IC, respectively). All data represent the mean&#x000b1;SD. (B) Monocytes from non-Jewish patients with <italic>A</italic> or <italic>B haplotypes</italic> were stimulated with IC for 16 h. Data are presented as &#x00025; of TL1A<sup>&#x0002b;</sup> monocytes (n&#x0200a;&#x0003d;&#x0200a;14 and 16 for <italic>haplotype A</italic> and <italic>haplotype B</italic>, respectively, P&#x0200a;&#x0003d;&#x0200a;0.83 and P&#x0200a;&#x0003d;&#x0200a;0.72 for control and IC, respectively). (C) Monocytes from Jewish patients with <italic>A</italic> or <italic>B haplotypes</italic> were stimulated with IC for 16 h. Data are presented as mean fluorescence intensity (MFI) (n&#x0200a;&#x0003d;&#x0200a;11 and 9 for <italic>haplotype A</italic> and <italic>haplotype B</italic>, respectively, P&#x0200a;&#x0003d;&#x0200a;0.66 and P&#x0200a;&#x0003d;&#x0200a;0.52 for control and IC, respectively). (D) Monocytes from non-Jewish patients with <italic>A</italic> or <italic>B haplotypes</italic> were stimulated with IC for 16 h. Data are presented as mean fluorescence intensity (MFI) (n&#x0200a;&#x0003d;&#x0200a;14 and 16 for <italic>haplotype A</italic> and <italic>haplotype B</italic>, respectively, P&#x0200a;&#x0003d;&#x0200a;0.56 and P&#x0200a;&#x0003d;&#x0200a;0.91 for control and IC, respectively).</p></caption><graphic xlink:href="pone.0004719.g003"/></fig><table-wrap id="pone-0004719-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004719.t002</object-id><label>Table 2</label><caption><title>Summary of significant differences for TL1A <italic>haplotypes A</italic> and <italic>B</italic> in CD patients stratified into Jewish and Non-Jewish</title></caption><graphic id="pone-0004719-t002-2" xlink:href="pone.0004719.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004719-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Jews</td><td align="left" rowspan="1" colspan="1">Non-Jews</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Soluble TL1A</bold></td><td align="left" rowspan="1" colspan="1">IC stimulation</td><td align="left" rowspan="1" colspan="1">IC stimulation</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">haplotype B &#x0003e;&#x0003e;&#x0003e; haplotype A<xref ref-type="table-fn" rid="nt102">&#x0002a;&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">haplotype B &#x0003e; haplotype A<xref ref-type="table-fn" rid="nt101">&#x0002a;</xref></td></tr></tbody></table><table-wrap-foot><fn id="nt101"><label>&#x0002a;</label><p>, <italic>p</italic>&#x02264;0.05</p></fn><fn id="nt102"><label>&#x0002a;&#x0002a;</label><p>, <italic>p</italic>&#x02264;0.005</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c"><title><italic>TNFSF15 (TL1A)</italic> haplotypes in Jewish OmpC&#x0002b; IBD patients result in differential TL1A expression in monocytes stimulated with IC</title><p>Since we observed a risk association for TL1A <italic>haplotype B</italic> in Jewish CD patients, and this association was accentuated in Jewish OmpC&#x0002b; patients, we subdivided the Jewish patients into OmpC&#x0002b; and OmpC&#x02212; patients and analyzed TL1A secretion and membrane expression for <italic>haplotypes A</italic> and <italic>B</italic>. We observed a significant increase in TL1A secretion in patients carrying the <italic>B haplotype</italic> compared to <italic>A</italic> carriers in Jewish OmpC&#x0002b; patients in response to IC (<xref ref-type="fig" rid="pone-0004719-g004">Figure 4A</xref>). Differences in TL1A secretion were most prominent at 6 h post stimulation compared to 16 h (<xref ref-type="fig" rid="pone-0004719-g004">Figure 4A</xref>, p&#x0200a;&#x0003d;&#x0200a;0.34). We observed a TL1A response in Jewish OmpC&#x0002b; patients heterozygous for <italic>haplotype A</italic> and <italic>B</italic> that was intermediate between that observed for patients carrying the <italic>A</italic> and <italic>B haplotype</italic>, respectively (data not shown). Jewish OmpC&#x02212; patients carrying the <italic>B haplotype</italic> also secreted higher levels of TL1A in response to IC than <italic>A</italic> carriers at 6 h post stimulation (<xref ref-type="fig" rid="pone-0004719-g004">Figure 4B</xref>, p&#x0200a;&#x0003d;&#x0200a;0.054 for 16 h IC stimulation), while non-Jewish OmpC&#x0002b; patients with the <italic>B haplotype</italic> secreted higher levels of TL1A at 16 h post stimulation (<xref ref-type="fig" rid="pone-0004719-g004">Figure 4C</xref>, p&#x0200a;&#x0003d;&#x0200a;0.14 for 6 h IC stimulation), suggesting different kinetics in the TL1A secretion in Jewish vs. non-Jewish CD patients in response to Fc&#x003b3;R signaling. We did not observe any differences in TL1A secretion in non-Jewish OmpC&#x02212; patients with the <italic>B haplotype</italic> compared to patients with <italic>haplotype A</italic> (<xref ref-type="fig" rid="pone-0004719-g004">Figure 4D</xref>, p&#x0200a;&#x0003d;&#x0200a;0.21 for 16 h IC stimulation).</p><fig id="pone-0004719-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004719.g004</object-id><label>Figure 4</label><caption><title>The <italic>B</italic> risk haplotype is associated with increased TL1A secretion in CD patient subgroups.</title><p>(A) Monocytes from Jewish OmpC&#x0002b; patients homozygous for <italic>haplotypes A</italic> or <italic>B</italic> were stimulated with IC for 6 or 16 h (n&#x0200a;&#x0003d;&#x0200a;7 for <italic>haplotype A</italic> and <italic>haplotype B</italic>, &#x0002a;, P&#x02264;0.001). Cell culture supernatants were analyzed for TL1A by ELISA. (B) Monocytes from Jewish OmpC&#x02212; patients homozygous for <italic>haplotype A</italic> or <italic>haplotype B</italic> were stimulated with IC for 6 or 16 h (n&#x0200a;&#x0003d;&#x0200a;8 and 5 for <italic>haplotype A</italic> and <italic>haplotype B</italic>, respectively, &#x0002a;, P&#x02264;0.05). (C) Monocytes from non-Jewish OmpC&#x0002b; patients with <italic>A</italic> or <italic>B</italic> haplotypes were stimulated with IC for 6 or 16 h (n&#x0200a;&#x0003d;&#x0200a;4 and 5 for <italic>haplotype A</italic> and <italic>haplotype B</italic>, respectively, &#x0002a;, P&#x02264;0.05). (D) Monocytes from non-Jewish OmpC&#x02212; patients with <italic>A</italic> or <italic>B haplotypes</italic> were stimulated with IC for 6 or 16 h (n&#x0200a;&#x0003d;&#x0200a;9 and 10 for <italic>A</italic> and <italic>B</italic>, respectively).</p></caption><graphic xlink:href="pone.0004719.g004"/></fig><p>Next, we analyzed the surface expression of TL1A in Jewish OmpC&#x0002b; patients with different haplotypes by flow cytometry (<xref ref-type="fig" rid="pone-0004719-g005">Figure 5</xref>). We observed a significant increase in the proportion of TL1A<sup>&#x0002b;</sup> monocytes in untreated monocytes from Jewish patients carrying the <italic>B haplotype</italic> compared to patients with the <italic>A haplotype</italic> in Jewish patients regardless of their OmpC status (<xref ref-type="fig" rid="pone-0004719-g005">Figure 5A, B</xref>). Similar differences were not seen in non-Jewish patients (<xref ref-type="fig" rid="pone-0004719-g005">Figure 5C, D</xref>, p&#x0200a;&#x0003d;&#x0200a;0.37 and p&#x0200a;&#x0003d;&#x0200a;0.43 for non-Jewish OmpC&#x0002b; and non-Jewish OmpC&#x02212; patients, respectively). Surprisingly, we could not observe any differences in the percentage of monocytes expressing TL1A stimulated with IC between different <italic>haplotypes</italic> (<xref ref-type="fig" rid="pone-0004719-g005">Figure 5A, B</xref>, p&#x0200a;&#x0003d;&#x0200a;0.31). However, the mean fluorescence intensity (MFI) was significantly increased in IC stimulated monocytes in Jewish OmpC&#x0002b; patients carrying the <italic>B haplotype</italic> compared to <italic>A</italic> carriers (<xref ref-type="fig" rid="pone-0004719-g005">Figure 5A</xref>) but not in Jewish OmpC&#x02212; patients (<xref ref-type="fig" rid="pone-0004719-g005">Figure 5B</xref>, p&#x0200a;&#x0003d;&#x0200a;0.35). We did not observe any significant differences in surface expression of TL1A in untreated or IC stimulated monocytes between <italic>A</italic> and <italic>B</italic> carriers in non-Jewish patients (<xref ref-type="fig" rid="pone-0004719-g005">Figure 5C, D</xref>, p&#x0200a;&#x0003d;&#x0200a;0.35 and p&#x0200a;&#x0003d;&#x0200a;0.36 for IC-stimulated monocytes from non-Jewish OmpC&#x0002b; patients, &#x00025; TL1A&#x0002b; monocytes and MFI, respectively, and p&#x0200a;&#x0003d;&#x0200a;0.68 and p&#x0200a;&#x0003d;&#x0200a;0.74 for IC-stimulated monocytes from non-Jewish OmpC&#x0002b; patients, &#x00025; TL1A&#x0002b; monocytes and MFI, respectively). In summary, Jewish OmpC&#x0002b; and OmpC&#x02212; <italic>haplotype B</italic> carriers secrete significantly more TL1A in response to IC compared to <italic>haplotype A</italic> carriers (<xref ref-type="table" rid="pone-0004719-t003">Table 3</xref>). Furthermore, the proportion of TL1A<sup>&#x0002b;</sup> monocytes in untreated monocytes is significantly increased in Jewish OmpC&#x0002b; and OmpC&#x02212; <italic>haplotype B</italic> carriers compared to Jewish OmpC&#x0002b; and OmpC&#x02212; <italic>haplotype A</italic> carriers. Additionally, the MFI of TL1A membrane expression was significantly increased in IC stimulated monocytes in Jewish OmpC&#x0002b; patients with the <italic>B haplotype</italic> compared to patients with the <italic>A haplotype</italic> (<xref ref-type="table" rid="pone-0004719-t003">Table 3</xref>).</p><fig id="pone-0004719-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004719.g005</object-id><label>Figure 5</label><caption><title>The <italic>B</italic> risk haplotype is associated with an increase in the number of TL1A&#x0002b; peripheral monocytes in Jewish but not in non-Jewish CD patients.</title><p>(A) Monocytes from Jewish OmpC&#x0002b; patients with <italic>A</italic> or <italic>B haplotypes</italic> were stimulated with IC for 16 h. Monocytes were stained with an anti-TL1A antibody and analyzed by flow cytometry. Data are presented as &#x00025; of TL1A<sup>&#x0002b;</sup> monocytes (left panel) or mean fluorescence intensity (MFI) (right panel) (n&#x0200a;&#x0003d;&#x0200a;6, or 7 for <italic>haplotype A</italic> or <italic>haplotype B</italic>, respectively, &#x0002a;, P&#x02264;0.05 for &#x00025; TL1A<sup>&#x0002b;</sup>; &#x0002a;, P&#x02264;0.02 for MFI). (B) Monocytes from Jewish OmpC&#x02212; patients with <italic>A</italic> or <italic>B haplotypes</italic> were stimulated with IC for 16 h. Data are presented as &#x00025; of TL1A<sup>&#x0002b;</sup> monocytes (left panel) or MFI (right panel). (n&#x0200a;&#x0003d;&#x0200a;9 or 6 for <italic>haplotype A</italic> or <italic>haplotype B</italic>, respectively, &#x0002a;, P&#x02264;0.05) (C) Monocytes from non-Jewish OmpC&#x0002b; patients with <italic>A</italic> or <italic>B haplotypes</italic> were stimulated with IC for 16 h. Data are presented as &#x00025; of TL1A<sup>&#x0002b;</sup> monocytes (left panel) or MFI (right panel). (n&#x0200a;&#x0003d;&#x0200a;5 or 6 for <italic>haplotype A</italic> or <italic>haplotype B</italic>, respectively). (D) Monocytes from non-Jewish OmpC&#x02212; patients with <italic>A</italic> or <italic>B haplotypes</italic> were stimulated with IC for 16 h. Data are presented as &#x00025; of TL1A<sup>&#x0002b;</sup> monocytes (left panel) or MFI (right panel). (n&#x0200a;&#x0003d;&#x0200a;9 or 11 for <italic>haplotype A</italic> or <italic>haplotype B</italic>, respectively).</p></caption><graphic xlink:href="pone.0004719.g005"/></fig><table-wrap id="pone-0004719-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004719.t003</object-id><label>Table 3</label><caption><title>Summary of significant differences for TL1A <italic>haplotypes A</italic> and <italic>B</italic> in CD patients sub-stratified into Jewish OmpC&#x0002b;/OmpC&#x02212; and non-Jewish OmpC&#x0002b;/OmpC&#x02212;</title></caption><graphic id="pone-0004719-t003-3" xlink:href="pone.0004719.t003"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004719-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Jews OmpC&#x0002b;</td><td align="left" rowspan="1" colspan="1">Jews OmpC&#x02212;</td><td align="left" rowspan="1" colspan="1">Non-Jews OmpC&#x0002b;</td><td align="left" rowspan="1" colspan="1">Non-Jews OmpC&#x02212;</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Soluble TL1A</bold></td><td align="left" rowspan="1" colspan="1">IC stimulation</td><td align="left" rowspan="1" colspan="1">IC stimulation</td><td align="left" rowspan="1" colspan="1">IC stimulation</td><td align="left" rowspan="1" colspan="1">IC stimulation</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">haplotype B &#x0003e; haplotype A<xref ref-type="table-fn" rid="nt105">&#x0002a;&#x0002a;&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">haplotype B &#x0003e; haplotype A<xref ref-type="table-fn" rid="nt103">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">haplotype B &#x0003e; haplotype A<xref ref-type="table-fn" rid="nt103">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td colspan="5" align="left" rowspan="1"><bold>Membrane TL1A</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>(</bold><bold><italic>&#x00025; TL1A&#x0002b; Monocytes)</italic></bold></td><td align="left" rowspan="1" colspan="1">baseline</td><td align="left" rowspan="1" colspan="1">baseline</td><td align="left" rowspan="1" colspan="1">baseline</td><td align="left" rowspan="1" colspan="1">baseline</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">haplotype B &#x0003e; haplotype A <xref ref-type="table-fn" rid="nt103">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">haplotype B &#x0003e; haplotype A <xref ref-type="table-fn" rid="nt103">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>(MFI)</italic></bold></td><td align="left" rowspan="1" colspan="1">IC stimulation</td><td align="left" rowspan="1" colspan="1">IC stimulation</td><td align="left" rowspan="1" colspan="1">IC stimulation</td><td align="left" rowspan="1" colspan="1">IC stimulation</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">haplotype B &#x0003e; haplotype A <xref ref-type="table-fn" rid="nt104">&#x0002a;&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr></tbody></table><table-wrap-foot><fn id="nt103"><label>&#x0002a;</label><p>, <italic>p</italic>&#x02264;0.05</p></fn><fn id="nt104"><label>&#x0002a;&#x0002a;</label><p>, <italic>p</italic>&#x02264;0.01</p></fn><fn id="nt105"><label>&#x0002a;&#x0002a;&#x0002a;</label><p>, <italic>p</italic>&#x02264;0.001</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4"><title>Discussion</title><p>Our findings demonstrate a direct association between genetic variation in the TL1A gene <italic>TNFSF15</italic>, and the induction of TL1A in Jewish, and particularly in OmpC&#x0002b; Jewish CD patients. Patients carrying the <italic>TNFSF15</italic> (<italic>TL1A</italic>) risk <italic>haplotype B</italic> have a significantly increased expression of membrane and soluble TL1A in response to IC. In the current era of finding genetic associations with disease using genome-wide association studies, our report also illustrates that detailed molecular phenotypic studies of patients with particular haplotypes will lead to the discovery of important functional differences that occur as a result of the different haplotypes.</p><p>We have previously reported that <italic>TNFSF15</italic> (<italic>TL1A</italic>) <italic>haplotype B</italic> is associated with a more severe disease phenotype in Jewish patients, as these individuals have a higher frequency of small bowel surgery <xref ref-type="bibr" rid="pone.0004719-Picornell1">&#x0005b;15&#x0005d;</xref>. Furthermore, <italic>TNFSF15 haplotype B</italic> is associated with increased risk of CD in Ashkenazi Jews (32&#x00025; in CD vs. 26&#x00025; in controls) but with a decreased risk in non-Jewish CD patients (39&#x00025; in CD vs. 50&#x00025; in controls) <xref ref-type="bibr" rid="pone.0004719-Picornell1">&#x0005b;15&#x0005d;</xref>. Here, we extend our findings and demonstrate that Jewish OmpC&#x0002b; CD patients (a group characterized by more severe disease) have a further increased frequency of <italic>haplotype B</italic> (also a group characterized by more severe disease) (42&#x00025; CD OmpC&#x0002b; vs. 25&#x00025; CD OmpC&#x02212;) suggesting that an antibody titer for the <italic>E. coli</italic> outer membrane porin C (OmpC) increases the risk of CD in Jewish patients carrying the <italic>B haplotype</italic>. We observed that this hierarchical relationship of <italic>TL1A</italic> risk <italic>haplotype B</italic> and OmpC titers in Jewish CD patients also applies to the functional response, e.g. the immune responses to Fc&#x003b3;R signaling in Jewish CD patients. In both Jewish and non-Jewish CD we observed a significant increase of TL1A secretion in <italic>haplotype B</italic> compared to <italic>haplotype A</italic>. However, we observed an earlier onset of TL1A secretion and an overall greater amount of TL1A secretion in Jewish patients with <italic>haplotype B</italic> compared to non-Jewish <italic>haplotype B</italic> carriers, suggesting different kinetics in the induction of TL1A expression in Jewish vs. non-Jewish patients carrying haplotype B (see <xref ref-type="table" rid="pone-0004719-t002">Table 2</xref> for data summary). When we further sub-stratified Jewish and non-Jewish patients into patient groups with or without positive serology for OmpC antibodies, this association of <italic>TL1A haplotype B</italic> and increased TL1A expression was further accentuated in Jewish OmpC&#x0002b; patients. Jewish OmpC&#x0002b; patients with <italic>haplotype B</italic> have increased secretion of soluble and enhanced expression of membrane TL1A in response to IC, as well as increased baseline membrane TL1A expression, when compared to <italic>haplotype A</italic> (see <xref ref-type="table" rid="pone-0004719-t003">Table 3</xref> for data summary). On the other hand Jewish OmpC&#x02212; patients with <italic>haplotype B</italic> have increased secretion of soluble TL1A in response to IC, and increased baseline membrane TL1A expression, but TL1A and membrane TL1A in response to IC are not significantly different when compared to <italic>haplotype A</italic>. In non-Jewish OmpC&#x0002b; patients with <italic>haplotype B</italic>, we only observed an increased secretion of soluble TL1A in response to IC, but with a distinct and delayed kinetics compared to Jewish OmpC&#x0002b; and OmpC&#x02212; patients of the same haplotype. The higher baseline expression of membrane TL1A on monocytes that we observed in Jewish but not non-Jewish CD patients carrying <italic>haplotype B</italic> might suggest a higher capacity of TL1A dependent T cell activation in these patients <xref ref-type="bibr" rid="pone.0004719-Prehn1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Prehn2">&#x0005b;7&#x0005d;</xref>.</p><p>Interestingly, we observed that the percentages of monocytes with TL1A surface expression being approximately twice as high in OmpC&#x02212; Jewish patients compared to OmpC&#x0002b; patients for either haplotype when stimulated with IC (<xref ref-type="fig" rid="pone-0004719-g005">Figures 5A, B</xref>). We analyzed the TL1A surface expression of monocytes in response to IC stimulation at a 16 h time-point. We have demonstrated that monocytes from Jewish OmpC&#x0002b; and OmpC&#x02212; patients have a faster induction of TL1A secretion compared to non-Jewish patients (<xref ref-type="fig" rid="pone-0004719-g002">Figures 2</xref>, <xref ref-type="fig" rid="pone-0004719-g004">4</xref>). We observed maximal induction of TL1A secretion in Jewish OmpC&#x0002b; patients at 6 h and a decline of TL1A secretion at 16 h. However, in Jewish OmpC&#x02212; patients we observed a further increase of TL1A secretion at 16 h (<xref ref-type="fig" rid="pone-0004719-g004">Figure 4 A and B</xref>). The mechanism for the differential induction in Jewish OmpC&#x0002b; vs. Jewish OmpC&#x02212; and Jewish vs. non-Jewish patients is currently unknown. The differences in surface expression in Jewish OmpC&#x0002b; vs. OmpC&#x02212; patients might therefore just reflect the differences in cleavage-kinetics of TL1A from the membrane due to higher turn-over of TL1A in Jewish OmpC&#x0002b; patients.</p><p>We previously published that <italic>TNFSF15 haplotype B</italic> is associated with increased risk of CD in Ashkenazi Jews but with a decreased risk in non-Jewish CD patients <xref ref-type="bibr" rid="pone.0004719-Picornell1">&#x0005b;15&#x0005d;</xref>. To our surprise, we did not observe a decrease in TL1A expression in <italic>haplotype B</italic> carriers in non-Jewish patients compared to <italic>haplotype A</italic> carriers as one would expect (<xref ref-type="fig" rid="pone-0004719-g002">Figures 2B</xref>, <xref ref-type="fig" rid="pone-0004719-g003">3B, 3D</xref>). However, from the data presented here we are concluding that Jewish CD patients demonstrate a faster TL1A induction than non-Jewish patients. We observed an increase of TL1A secretion at 16 h compared to 6 h post IC-stimulation in non-Jewish patients suggesting a maximal secretion at 16 h. However, we did not analyze the TL1A secretion beyond the 16 h time-point and it might be possible that in non-Jewish patients the maximal secretion of TL1A is reached beyond 16 h. Therefore, it cannot be excluded that a difference between TL1A secretion in haplotype A and B might occur at a later time-point in non-Jewish patients. Furthermore, based on our data we hypothesize that TL1A is a CD severity more importantly than susceptibility gene. We have previously demonstrated that <italic>TNFSF15 haplotype B</italic> is associated with increased risk of CD in Jews but with a decreased risk in non-Jewish CD patients <xref ref-type="bibr" rid="pone.0004719-Picornell1">&#x0005b;15&#x0005d;</xref>. However, when we analyzed haplotype association with disease severity, as measured by clinical parameters (fibrostenosis, internal perforation, perianal penetration, small bowel surgeries), no association was observed between haplotypes in non-Jewish patients but association was observed in Jewish CD patients carrying haplotype B <xref ref-type="bibr" rid="pone.0004719-Picornell1">&#x0005b;15&#x0005d;</xref>. These data are consistent with our findings of no significant differences in TL1A expression in non-Jewish patients.</p><p>The <italic>TNFSF15</italic> genetic variation and TL1A functional changes observed here are of importance in the context of the recent demonstration that the <italic>IL23R</italic> gene is a major determinant of CD susceptibility <xref ref-type="bibr" rid="pone.0004719-Barrett1">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Duerr1">&#x0005b;33&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Rioux1">&#x0005b;34&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Consortium1">&#x0005b;35&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Dubinsky1">&#x0005b;36&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Parkes1">&#x0005b;37&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Xavier1">&#x0005b;38&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Taylor1">&#x0005b;39&#x0005d;</xref>. In particular, we have been able to demonstrate that TL1A synergizes with IL-23 to induce IL-17 production by CD4&#x0002b; T cells in a mouse model of chronic colitis <xref ref-type="bibr" rid="pone.0004719-Takedatsu1">&#x0005b;8&#x0005d;</xref>. Furthermore, these observations are consistent with the role of TL1A during the development of chronic colitis in mice. We have been able to demonstrate that administration of neutralizing TL1A antibodies not only prevents but also treats established chronic colitis, likely by directly blocking IFN-&#x003b3; production by T<sub>H</sub>1 cells and IL-17 and IL-6 production from T<sub>H</sub>17 cells, and also by blocking the enhancing effect of TL1A/IL-12 and TL1A/IL-23 on these CD4<sup>&#x0002b;</sup> T cell subsets <xref ref-type="bibr" rid="pone.0004719-Takedatsu1">&#x0005b;8&#x0005d;</xref>. These data support the notion that TL1A expression is increased during chronic mucosal inflammation and that leads to further activation of TH1 and TH17 cells.</p><p>In this study, we demonstrated that there is a direct association between genetic variants of the <italic>TL1A</italic> gene and the induction of TL1A in Jewish CD patients. Since the induction of TL1A gene expression seems to be restricted to stimulation by Fc&#x003b3;R signaling and/or enteric bacteria <xref ref-type="bibr" rid="pone.0004719-Prehn2">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Cassatella1">&#x0005b;40&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004719-Shih1">&#x0005b;41&#x0005d;</xref>, blockage of TL1A might have therapeutic benefit in IBD patients without markedly increasing the susceptibility to infection. Defining CD patients by ethnicity, serotyping, and genotyping, will allow us to identify patients with the potential for higher TL1A response to immune complexes and commensal bacteria and hence may well identify those CD patients that would respond best to therapeutic blockade of TL1A function.</p></sec></body><back><ack><p>We would like to thank IBD patients at Cedars-Sinai Medical Center and other study participants whose contribution made this work possible. The authors would like to thank Teva Pharmaceutical USA (North Wales, PA) for generously providing us with the TL1A antibodies.</p></ack><ref-list><title>References</title><ref id="pone.0004719-Migone1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Migone</surname><given-names>TS</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Zhuang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><etal/></person-group><year>2002</year><article-title>TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator.</article-title><source>Immunity</source><volume>16</volume><fpage>479</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">11911831</pub-id></citation></ref><ref id="pone.0004719-Bamias1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bamias</surname><given-names>G</given-names></name><name><surname>Martin</surname><given-names>C</given-names><suffix>3rd</suffix></name><name><surname>Marini</surname><given-names>M</given-names></name><name><surname>Hoang</surname><given-names>S</given-names></name><name><surname>Mishina</surname><given-names>M</given-names></name><etal/></person-group><year>2003</year><article-title>Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease.</article-title><source>J Immunol</source><volume>171</volume><fpage>4868</fpage><lpage>4874</lpage><pub-id pub-id-type="pmid">14568967</pub-id></citation></ref><ref id="pone.0004719-Papadakis1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Papadakis</surname><given-names>KA</given-names></name><name><surname>Prehn</surname><given-names>JL</given-names></name><name><surname>Landers</surname><given-names>C</given-names></name><name><surname>Han</surname><given-names>Q</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><etal/></person-group><year>2004</year><article-title>TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells.</article-title><source>J Immunol</source><volume>172</volume><fpage>7002</fpage><lpage>7007</lpage><pub-id pub-id-type="pmid">15153521</pub-id></citation></ref><ref id="pone.0004719-Papadakis2"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Papadakis</surname><given-names>KA</given-names></name><name><surname>Zhu</surname><given-names>D</given-names></name><name><surname>Prehn</surname><given-names>JL</given-names></name><name><surname>Landers</surname><given-names>C</given-names></name><name><surname>Avanesyan</surname><given-names>A</given-names></name><etal/></person-group><year>2005</year><article-title>Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9&#x0002b; T lymphocytes.</article-title><source>J Immunol</source><volume>174</volume><fpage>4985</fpage><lpage>4990</lpage><pub-id pub-id-type="pmid">15814728</pub-id></citation></ref><ref id="pone.0004719-Prehn1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prehn</surname><given-names>JL</given-names></name><name><surname>Mehdizadeh</surname><given-names>S</given-names></name><name><surname>Landers</surname><given-names>CJ</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Cha</surname><given-names>SC</given-names></name><etal/></person-group><year>2004</year><article-title>Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation.</article-title><source>Clin Immunol</source><volume>112</volume><fpage>66</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">15207783</pub-id></citation></ref><ref id="pone.0004719-Bamias2"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bamias</surname><given-names>G</given-names></name><name><surname>Mishina</surname><given-names>M</given-names></name><name><surname>Nyce</surname><given-names>M</given-names></name><name><surname>Ross</surname><given-names>WG</given-names></name><name><surname>Kollias</surname><given-names>G</given-names></name><etal/></person-group><year>2006</year><article-title>Role of TL1A and its receptor DR3 in two models of chronic murine ileitis.</article-title><source>Proc Natl Acad Sci U S A</source><volume>103</volume><fpage>8441</fpage><lpage>8446</lpage><pub-id pub-id-type="pmid">16698931</pub-id></citation></ref><ref id="pone.0004719-Prehn2"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prehn</surname><given-names>JL</given-names></name><name><surname>Thomas</surname><given-names>LS</given-names></name><name><surname>Landers</surname><given-names>CJ</given-names></name><name><surname>Yu</surname><given-names>QT</given-names></name><name><surname>Michelsen</surname><given-names>KS</given-names></name><etal/></person-group><year>2007</year><article-title>The T Cell Costimulator TL1A Is Induced by Fc{gamma}R Signaling in Human Monocytes and Dendritic Cells.</article-title><source>J Immunol</source><volume>178</volume><fpage>4033</fpage><lpage>4038</lpage><pub-id pub-id-type="pmid">17371957</pub-id></citation></ref><ref id="pone.0004719-Takedatsu1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takedatsu</surname><given-names>H</given-names></name><name><surname>Michelsen</surname><given-names>KS</given-names></name><name><surname>Wei</surname><given-names>B</given-names></name><name><surname>Landers</surname><given-names>CJ</given-names></name><name><surname>Thomas</surname><given-names>LS</given-names></name><etal/></person-group><year>2008</year><article-title>TL1A (TNFSF15) Regulates the Development of Chronic Colitis by Modulating Both T-Helper 1 and T-Helper 17 Activation.</article-title><source>Gastroenterology</source><volume>135</volume><fpage>552</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">18598698</pub-id></citation></ref><ref id="pone.0004719-Fang1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>L</given-names></name><name><surname>Adkins</surname><given-names>B</given-names></name><name><surname>Deyev</surname><given-names>V</given-names></name><name><surname>Podack</surname><given-names>ER</given-names></name></person-group><year>2008</year><article-title>Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation.</article-title><source>J Exp Med</source><volume>205</volume><fpage>1037</fpage><lpage>1048</lpage><pub-id pub-id-type="pmid">18411341</pub-id></citation></ref><ref id="pone.0004719-Meylan1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meylan</surname><given-names>F</given-names></name><name><surname>Davidson</surname><given-names>TS</given-names></name><name><surname>Kahle</surname><given-names>E</given-names></name><name><surname>Kinder</surname><given-names>M</given-names></name><name><surname>Acharya</surname><given-names>K</given-names></name><etal/></person-group><year>2008</year><article-title>The TNF-Family Receptor DR3 is Essential for Diverse T Cell-Mediated Inflammatory Diseases.</article-title><source>Immunity</source></citation></ref><ref id="pone.0004719-Pappu1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pappu</surname><given-names>BP</given-names></name><name><surname>Borodovsky</surname><given-names>A</given-names></name><name><surname>Zheng</surname><given-names>TS</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><etal/></person-group><year>2008</year><article-title>TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease.</article-title><source>J Exp Med</source><volume>205</volume><fpage>1049</fpage><lpage>1062</lpage><pub-id pub-id-type="pmid">18411337</pub-id></citation></ref><ref id="pone.0004719-Yamazaki1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamazaki</surname><given-names>K</given-names></name><name><surname>McGovern</surname><given-names>D</given-names></name><name><surname>Ragoussis</surname><given-names>J</given-names></name><name><surname>Paolucci</surname><given-names>M</given-names></name><name><surname>Butler</surname><given-names>H</given-names></name><etal/></person-group><year>2005</year><article-title>Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease.</article-title><source>Hum Mol Genet</source><volume>14</volume><fpage>3499</fpage><lpage>3506</lpage><pub-id pub-id-type="pmid">16221758</pub-id></citation></ref><ref id="pone.0004719-Kakuta1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kakuta</surname><given-names>Y</given-names></name><name><surname>Kinouchi</surname><given-names>Y</given-names></name><name><surname>Negoro</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Shimosegawa</surname><given-names>T</given-names></name></person-group><year>2006</year><article-title>Association study of TNFSF15 polymorphisms in Japanese patients with inflammatory bowel disease.</article-title><source>Gut</source><volume>55</volume><fpage>1527</fpage><lpage>1528</lpage><pub-id pub-id-type="pmid">16966713</pub-id></citation></ref><ref id="pone.0004719-Barrett1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Hansoul</surname><given-names>S</given-names></name><name><surname>Nicolae</surname><given-names>DL</given-names></name><name><surname>Cho</surname><given-names>JH</given-names></name><name><surname>Duerr</surname><given-names>RH</given-names></name><etal/></person-group><year>2008</year><article-title>Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease.</article-title><source>Nat Genet</source></citation></ref><ref id="pone.0004719-Picornell1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Picornell</surname><given-names>Y</given-names></name><name><surname>Mei</surname><given-names>L</given-names></name><name><surname>Taylor</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Targan</surname><given-names>SR</given-names></name><etal/></person-group><year>2007</year><article-title>TNFSF15 is an ethnic-specific IBD gene.</article-title><source>Inflamm Bowel Dis</source><volume>13</volume><fpage>1333</fpage><lpage>1338</lpage><pub-id pub-id-type="pmid">17663424</pub-id></citation></ref><ref id="pone.0004719-Funke1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Funke</surname><given-names>B</given-names></name><name><surname>Finn</surname><given-names>CT</given-names></name><name><surname>Plocik</surname><given-names>AM</given-names></name><name><surname>Lake</surname><given-names>S</given-names></name><name><surname>DeRosse</surname><given-names>P</given-names></name><etal/></person-group><year>2004</year><article-title>Association of the DTNBP1 locus with schizophrenia in a U.S. population.</article-title><source>Am J Hum Genet</source><volume>75</volume><fpage>891</fpage><lpage>898</lpage><pub-id pub-id-type="pmid">15362017</pub-id></citation></ref><ref id="pone.0004719-Li1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Sham</surname><given-names>PC</given-names></name><etal/></person-group><year>2005</year><article-title>Identifying potential risk haplotypes for schizophrenia at the DTNBP1 locus in Han Chinese and Scottish populations.</article-title><source>Mol Psychiatry</source><volume>10</volume><fpage>1037</fpage><lpage>1044</lpage><pub-id pub-id-type="pmid">16044171</pub-id></citation></ref><ref id="pone.0004719-Ober1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ober</surname><given-names>C</given-names></name><name><surname>Leavitt</surname><given-names>SA</given-names></name><name><surname>Tsalenko</surname><given-names>A</given-names></name><name><surname>Howard</surname><given-names>TD</given-names></name><name><surname>Hoki</surname><given-names>DM</given-names></name><etal/></person-group><year>2000</year><article-title>Variation in the interleukin 4-receptor alpha gene confers susceptibility to asthma and atopy in ethnically diverse populations.</article-title><source>Am J Hum Genet</source><volume>66</volume><fpage>517</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">10677312</pub-id></citation></ref><ref id="pone.0004719-Silverberg1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silverberg</surname><given-names>MS</given-names></name><name><surname>Duerr</surname><given-names>RH</given-names></name><name><surname>Brant</surname><given-names>SR</given-names></name><name><surname>Bromfield</surname><given-names>G</given-names></name><name><surname>Datta</surname><given-names>LW</given-names></name><etal/></person-group><year>2007</year><article-title>Refined genomic localization and ethnic differences observed for the IBD5 association with Crohn's disease.</article-title><source>Eur J Hum Genet</source><volume>15</volume><fpage>328</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">17213842</pub-id></citation></ref><ref id="pone.0004719-Sugimura1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sugimura</surname><given-names>K</given-names></name><name><surname>Taylor</surname><given-names>KD</given-names></name><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Hang</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><etal/></person-group><year>2003</year><article-title>A novel NOD2/CARD15 haplotype conferring risk for Crohn disease in Ashkenazi Jews.</article-title><source>Am J Hum Genet</source><volume>72</volume><fpage>509</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">12577202</pub-id></citation></ref><ref id="pone.0004719-Tountas1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tountas</surname><given-names>NA</given-names></name><name><surname>Casini-Raggi</surname><given-names>V</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Di Giovine</surname><given-names>FS</given-names></name><name><surname>Vecchi</surname><given-names>M</given-names></name><etal/></person-group><year>1999</year><article-title>Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis.</article-title><source>Gastroenterology</source><volume>117</volume><fpage>806</fpage><lpage>813</lpage><pub-id pub-id-type="pmid">10500062</pub-id></citation></ref><ref id="pone.0004719-VanDenBogaert1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Den Bogaert</surname><given-names>A</given-names></name><name><surname>Schumacher</surname><given-names>J</given-names></name><name><surname>Schulze</surname><given-names>TG</given-names></name><name><surname>Otte</surname><given-names>AC</given-names></name><name><surname>Ohlraun</surname><given-names>S</given-names></name><etal/></person-group><year>2003</year><article-title>The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease.</article-title><source>Am J Hum Genet</source><volume>73</volume><fpage>1438</fpage><lpage>1443</lpage><pub-id pub-id-type="pmid">14618545</pub-id></citation></ref><ref id="pone.0004719-Mow1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mow</surname><given-names>WS</given-names></name><name><surname>Vasiliauskas</surname><given-names>EA</given-names></name><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Fleshner</surname><given-names>PR</given-names></name><name><surname>Papadakis</surname><given-names>KA</given-names></name><etal/></person-group><year>2004</year><article-title>Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease.</article-title><source>Gastroenterology</source><volume>126</volume><fpage>414</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">14762777</pub-id></citation></ref><ref id="pone.0004719-Arnott1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnott</surname><given-names>ID</given-names></name><name><surname>Landers</surname><given-names>CJ</given-names></name><name><surname>Nimmo</surname><given-names>EJ</given-names></name><name><surname>Drummond</surname><given-names>HE</given-names></name><name><surname>Smith</surname><given-names>BK</given-names></name><etal/></person-group><year>2004</year><article-title>Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype.</article-title><source>Am J Gastroenterol</source><volume>99</volume><fpage>2376</fpage><lpage>2384</lpage><pub-id pub-id-type="pmid">15571586</pub-id></citation></ref><ref id="pone.0004719-Roth1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>MP</given-names></name><name><surname>Petersen</surname><given-names>GM</given-names></name><name><surname>McElree</surname><given-names>C</given-names></name><name><surname>Vadheim</surname><given-names>CM</given-names></name><name><surname>Panish</surname><given-names>JF</given-names></name><etal/></person-group><year>1989</year><article-title>Familial empiric risk estimates of inflammatory bowel disease in Ashkenazi Jews.</article-title><source>Gastroenterology</source><volume>96</volume><fpage>1016</fpage><lpage>1020</lpage><pub-id pub-id-type="pmid">2925048</pub-id></citation></ref><ref id="pone.0004719-Yang1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>McElree</surname><given-names>C</given-names></name><name><surname>Roth</surname><given-names>MP</given-names></name><name><surname>Shanahan</surname><given-names>F</given-names></name><name><surname>Targan</surname><given-names>SR</given-names></name><etal/></person-group><year>1993</year><article-title>Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews.</article-title><source>Gut</source><volume>34</volume><fpage>517</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">8491401</pub-id></citation></ref><ref id="pone.0004719-Fan1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>JB</given-names></name><name><surname>Gunderson</surname><given-names>KL</given-names></name><name><surname>Bibikova</surname><given-names>M</given-names></name><name><surname>Yeakley</surname><given-names>JM</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><year>2006</year><article-title>Illumina universal bead arrays.</article-title><source>Methods Enzymol</source><volume>410</volume><fpage>57</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">16938546</pub-id></citation></ref><ref id="pone.0004719-Shen1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>R</given-names></name><name><surname>Fan</surname><given-names>JB</given-names></name><name><surname>Campbell</surname><given-names>D</given-names></name><name><surname>Chang</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><year>2005</year><article-title>High-throughput SNP genotyping on universal bead arrays.</article-title><source>Mutat Res</source><volume>573</volume><fpage>70</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">15829238</pub-id></citation></ref><ref id="pone.0004719-Kutyavin1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kutyavin</surname><given-names>IV</given-names></name><name><surname>Afonina</surname><given-names>IA</given-names></name><name><surname>Mills</surname><given-names>A</given-names></name><name><surname>Gorn</surname><given-names>VV</given-names></name><name><surname>Lukhtanov</surname><given-names>EA</given-names></name><etal/></person-group><year>2000</year><article-title>3&#x02032;-minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures.</article-title><source>Nucleic Acids Res</source><volume>28</volume><fpage>655</fpage><lpage>661</lpage><pub-id pub-id-type="pmid">10606668</pub-id></citation></ref><ref id="pone.0004719-Livak1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name></person-group><year>1999</year><article-title>Allelic discrimination using fluorogenic probes and the 5&#x02032; nuclease assay.</article-title><source>Genet Anal</source><volume>14</volume><fpage>143</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">10084106</pub-id></citation></ref><ref id="pone.0004719-Landers1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Landers</surname><given-names>CJ</given-names></name><name><surname>Cohavy</surname><given-names>O</given-names></name><name><surname>Misra</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>YC</given-names></name><etal/></person-group><year>2002</year><article-title>Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens.</article-title><source>Gastroenterology</source><volume>123</volume><fpage>689</fpage><lpage>699</lpage><pub-id pub-id-type="pmid">12198693</pub-id></citation></ref><ref id="pone.0004719-Mei1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mei</surname><given-names>L</given-names></name><name><surname>Targan</surname><given-names>SR</given-names></name><name><surname>Landers</surname><given-names>CJ</given-names></name><name><surname>Dutridge</surname><given-names>D</given-names></name><name><surname>Ippoliti</surname><given-names>A</given-names></name><etal/></person-group><year>2006</year><article-title>Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease.</article-title><source>Gastroenterology</source><volume>130</volume><fpage>1078</fpage><lpage>1085</lpage><pub-id pub-id-type="pmid">16618402</pub-id></citation></ref><ref id="pone.0004719-Duerr1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duerr</surname><given-names>RH</given-names></name><name><surname>Taylor</surname><given-names>KD</given-names></name><name><surname>Brant</surname><given-names>SR</given-names></name><name><surname>Rioux</surname><given-names>JD</given-names></name><name><surname>Silverberg</surname><given-names>MS</given-names></name><etal/></person-group><year>2006</year><article-title>A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.</article-title><source>Science</source><volume>314</volume><fpage>1461</fpage><lpage>1463</lpage><pub-id pub-id-type="pmid">17068223</pub-id></citation></ref><ref id="pone.0004719-Rioux1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rioux</surname><given-names>JD</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Taylor</surname><given-names>KD</given-names></name><name><surname>Silverberg</surname><given-names>MS</given-names></name><name><surname>Goyette</surname><given-names>P</given-names></name><etal/></person-group><year>2007</year><article-title>Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis.</article-title><source>Nat Genet</source><volume>39</volume><fpage>596</fpage><lpage>604</lpage><pub-id pub-id-type="pmid">17435756</pub-id></citation></ref><ref id="pone.0004719-Consortium1"><label>35</label><citation citation-type="journal"><collab>Consortium TWTCC</collab><year>2007</year><article-title>Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.</article-title><source>Nature</source><volume>447</volume><fpage>661</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">17554300</pub-id></citation></ref><ref id="pone.0004719-Dubinsky1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dubinsky</surname><given-names>MC</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Picornell</surname><given-names>Y</given-names></name><name><surname>Wrobel</surname><given-names>I</given-names></name><name><surname>Katzir</surname><given-names>L</given-names></name><etal/></person-group><year>2007</year><article-title>IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease.</article-title><source>Inflamm Bowel Dis</source><volume>13</volume><fpage>511</fpage><lpage>515</lpage><pub-id pub-id-type="pmid">17309073</pub-id></citation></ref><ref id="pone.0004719-Parkes1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parkes</surname><given-names>M</given-names></name><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Prescott</surname><given-names>NJ</given-names></name><name><surname>Tremelling</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>CA</given-names></name><etal/></person-group><year>2007</year><article-title>Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility.</article-title><source>Nat Genet</source><volume>39</volume><fpage>830</fpage><lpage>832</lpage><pub-id pub-id-type="pmid">17554261</pub-id></citation></ref><ref id="pone.0004719-Xavier1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Podolsky</surname><given-names>DK</given-names></name></person-group><year>2007</year><article-title>Unravelling the pathogenesis of inflammatory bowel disease.</article-title><source>Nature</source><volume>448</volume><fpage>427</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">17653185</pub-id></citation></ref><ref id="pone.0004719-Taylor1"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>KD</given-names></name><name><surname>Targan</surname><given-names>SR</given-names></name><name><surname>Mei</surname><given-names>L</given-names></name><name><surname>Ippoliti</surname><given-names>AF</given-names></name><name><surname>McGovern</surname><given-names>D</given-names></name><etal/></person-group><year>2008</year><article-title>IL23R haplotypes provide a large population attributable risk for Crohn's disease.</article-title><source>Inflamm Bowel Dis</source></citation></ref><ref id="pone.0004719-Cassatella1"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cassatella</surname><given-names>MA</given-names></name><name><surname>da Silva</surname><given-names>GP</given-names></name><name><surname>Tinazzi</surname><given-names>I</given-names></name><name><surname>Facchetti</surname><given-names>F</given-names></name><name><surname>Scapini</surname><given-names>P</given-names></name><etal/></person-group><year>2007</year><article-title>Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis.</article-title><source>J Immunol</source><volume>178</volume><fpage>7325</fpage><lpage>7333</lpage><pub-id pub-id-type="pmid">17513783</pub-id></citation></ref><ref id="pone.0004719-Shih1"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shih</surname><given-names>DQ</given-names></name><name><surname>Kwan</surname><given-names>LY</given-names></name><name><surname>Chang</surname><given-names>EY</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Saruta</surname><given-names>M</given-names></name><etal/></person-group><year>2008</year><article-title>Mechanisms of Induction of Inflammatory Bowel Disease Associated Gene TL1A (TNFSF15) By Microbes in Antigen Presenting Cells.</article-title><source>Gastroenterology, Supplement</source><volume>134</volume><fpage>A-23</fpage></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was supported by NIH grants DK056328 (S.R.T.) and DK046763 (S.R.T., J.I.R.) and in part by the Cedars-Sinai Board of Governor's Chair in Medical Genetics (J.I.R.). Genotyping was supported in part by the General Clinical Research Center Genotyping Core (RR000425). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article> 